Protara (TARA) CFO Fabbio has 3,063 RSU shares withheld for taxes

Rhea-AI Filing Summary

Protara Therapeutics Chief Financial Officer reports tax-related share withholding. On January 20, 2026, CFO Patrick Fabbio had 3,063 shares of common stock withheld by Protara Therapeutics to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 19, 2024. The shares were treated as a disposition at $5.60 per share, and Fabbio now directly holds 67,376 shares of Protara Therapeutics common stock after this administrative transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fabbio Patrick

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		F		3,063(1)	D	$5.6	67,376	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2024.

Remarks:

	/s/ Patrick Fabbio	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protara Therapeutics (TARA) disclose for January 20, 2026?

Protara Therapeutics disclosed that its Chief Financial Officer, Patrick Fabbio, had 3,063 shares of common stock withheld on January 20, 2026 to satisfy income tax obligations related to a restricted stock unit vesting.

Was the Protara Therapeutics (TARA) CFO’s Form 4 transaction an open-market sale?

No. The Form 4 states the 3,063 shares were withheld by the issuer to cover income tax obligations from the vesting of a restricted stock unit award, rather than an open-market sale.

How many Protara Therapeutics (TARA) shares does CFO Patrick Fabbio own after this Form 4 transaction?

After the tax withholding of 3,063 shares, Chief Financial Officer Patrick Fabbio directly holds 67,376 shares of Protara Therapeutics common stock.

What was the price used for the Protara Therapeutics (TARA) share withholding on the Form 4?

The insider transaction reports the 3,063 withheld shares at a price of $5.60 per share for Protara Therapeutics common stock.

What award triggered the share withholding reported in the Protara Therapeutics (TARA) Form 4?

The footnote explains the withheld 3,063 shares relate to income tax obligations from the vesting of a restricted stock unit award granted to Patrick Fabbio on January 19, 2024.